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Abstract
Aims/hypothesis Multiple genetic variants are associated
with type 2 diabetes-related traits in Europeans, but their
role in South Asian populations needs further study. We
hypothesised that genetic variants associated with diabetes-
related traits in Europeans would explain a similar propor-
tion of phenotypic variance in a Pakistani population and
could be used in Mendelian randomisation analyses.
Methods We used data from 2,131 individuals from the Con-
trol of Blood Pressure and Risk Attenuation Trial (COBRA) in
Karachi, Pakistan. Individuals were aged 40 years or older.
Results Combining information from multiple genetic var-
iants showed that fasting glucose, BMI, triacylglycerol, and
systolic and diastolic blood pressure variants explained
2.9%, 0.7%, 5.5%, 1.2% and 1.8% of the variance in those
traits respectively. Genetic risk scores of fasting glucose,
triacylglycerol, BMI, systolic blood pressure and diastolic
blood pressure variants were associated with these traits,
with per allele SD effects of 0.057 (95% CI 0.041, 0.074),
p03.44×10−12, 0.130 (95% CI 0.105, 0.155), p02.9×10−21,
0.04 (95% CI 0.014, 0.072), p00.004, 0.031 (95% CI 0.016,
0.047), p07.9×10−5, 0.028 (95% CI 0.015, 0.042),
p05.5×10−5, respectively. These effects are consistent with
those observed in Europeans, except that the effect of tri-
acylglycerol variants in South Asians was slightly lower.
Mendelian randomisation provided evidence that genetically
influenced, raised triacylglycerol levels do not causally affect
type 2 diabetes risk to the extent predicted from observational
data (p00.0003 for difference between observed and instru-
mental variables correlations).
Conclusions/interpretation Genetic variants identified in
Europeans are associated with type 2 diabetes-related
traits in Pakistanis, with comparable effect sizes. Larger
studies are needed to perform adequately powered Mendelian
randomisation and help dissect the relationships between
type 2 diabetes-related traits in diverse South Asian
subgroups.
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Introduction
The risk of type 2 diabetes is particularly elevated in South
Asians compared with Western populations and is associat-
ed with greater morbidity and mortality rates [1]. About
20% of persons aged 40 years and older have diabetes in
Pakistan, making it the seventh highest ranking country in
terms of the global burden of diabetes. Interestingly, the
interrelationships between intermediate metabolic traits
such as BMI, blood pressure, lipids and glucose are incon-
sistent within different ethnic subgroups of South Asian
populations compared with those observed in European-
origin populations. For example, we have shown that
Pakistani ethnic subgroups with the greatest burden of
hypertension have the lowest relative prevalence of diabetes
[2].
Genetic variants may be useful in helping us understand
the complex relationships between metabolic traits and why
these relationships may differ across populations. There are
several reasons for further testing the role of genetic variants
in type 2 diabetes-related traits in South Asian populations.
First, genetic variants are randomly sorted in meiosis and are
independent of non-genetic factors, including environmental
risk factors, confounding factors or disease processes. This
principle of Mendelian randomisation has been used to
assess the causal relationship between several related meta-
bolic phenotypes, e.g. C-reactive protein and heart disease
[3], and sex hormone-binding globulin levels and diabetes
[4]. Most recently, studies have combined multiple risk
variants in a ‘genetic risk score’ to provide more power
compared with individual variants. These studies have
assessed the role of glucose in subclinical atherosclerosis
[5] and triacylglycerol in type 2 diabetes [6]. Second, large
meta-analyses of genome-wide association studies (GWAS)
have recently increased the number of common variants
robustly associated with type 2 diabetes-related quantitative
traits to more than 100. These also include 95, 32 and 16
variants associated with lipid measures, BMI and fasting
glucose, respectively, and most recently 29 variants associ-
ated with blood pressure [7–10]. Some of these large [10]
meta-analyses showed that common variants identified in
Europeans are associated with similar effect sizes in other
ethnic groups [11, 12], but these studies tended to focus on
single traits. Third, while individual common variants iden-
tified by GWAS have small effects with regard to the asso-
ciated phenotype, they can, when combined, explain a more
substantial proportion of phenotypic variance. For example,
genetic loci associated with triacylglycerol or fasting glu-
cose levels explain ∼7.4% and ∼3% of the variance in
triacylglycerol [9] and fasting glucose [7] levels in European
populations, respectively. These effects are similar in mag-
nitude to well established risk factors, such as the effect of
BMI on fasting glucose levels [13].
Testing variants against diabetes-related traits can be
useful to help understand the relationship between those
traits and how those relationships differ across ethnic
groups. Thus, with regard to the FTO variant known to be
associated with BMI in Europeans, we have recently shown
that its association with type 2 diabetes differs between
Europeans and South Asians, probably because BMI is a
poorer surrogate of adiposity in South Asians [14].
The objectives of this study were: (1) to determine the
extent to which genetic risk scores based on common gene
variants detected in European-origin populations explain
phenotypic variance in type 2 diabetes-related traits in a
South Asian context; and (2) to use these genetic risk scores
to detect any potential causal relationships of substantial
magnitude in Mendelian randomisation analyses in South
Asians. We used individual data from the Control of Blood
Pressure and Risk Attenuation Trial (COBRA) cohort study
in Karachi, a population-based study with measures of mul-
tiple metabolic traits and consisting of 2,073 (72%) partic-
ipants of Muhajir ethnicity. We focused on three traits
strongly associated with type 2 diabetes: fasting glucose
levels, BMI and triacylglycerol levels. We also used the
most recently identified blood pressure variants [12],
because of the strong association between these traits in
different ethnic subgroups in Pakistan [2].
Methods
Details of participants are given in Table 1 and Fig. 1.
Ethical approval was obtained from the Ethics Review
Committee at the Aga Khan University, Karachi, Pakistan.
Study design
A population-based sample representative of adults in Karachi
was recruited in a cluster randomised trial of strategies for
control of hypertension (COBRA, ClinicalTrials.gov ID no.
NCT00327574). The sampling details have been described
previously [15]. Briefly, a multi-stage cluster random sam-
pling design was used to randomly select 12 geographical
clusters in Karachi, the largest metropolitan city in Pakistan.
A census was done and a listing made of all individuals from
all households in the selected areas. All participants aged
40 years or above and residing in the same household were
invited to participate in the study by trained community health
workers. All participants were evaluated after obtaining in-
formed consent. A range of anthropometric and biochemical
data were collected from all consenting participants, with and
without hypertension, who had been screened for eligibility
for the trial. The enrolled group was categorised according to
the five main Pakistani ethnic subgroups into Muhajirs,
Punjabis, Sindhis, Baluchis, Pashtun and others (Table 1)
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[16, 17]. The numbers of individuals involved differed
slightly by trait, as genotyping success rates differed slightly
and individuals with diabetes had to be excluded from the
fasting glucose analysis.
SNP selection
We only selected single nucleotide polymorphisms (SNPs)
from GWAS studies of European individuals because these
studies include the majority of GWAS findings. We aimed to
test the effects of SNPs identified through European GWAS
in Pakistanis. We selected the ten SNPs most strongly asso-
ciated with triacylglycerol levels [8, 9] (excluding FADS1
rs174547 and GCKR rs1260326 because they are strongly
associated with several other quantitative traits relevant to
diabetes), the five SNPs most strongly associated with BMI
[10], 16 SNPs associated with fasting glucose [7] and 29
SNPs associated with blood pressure [12].
Genotyping
We genotyped all SNPs except the five BMI SNPs, using a
modified Taqman assay, KASPAR assay (www.kbioscience.
co.uk). The five BMI SNPs were genotyped using a pre-
designed Taqman SNP genotyping assay from Applied Bio-
systems (Warrington, UK), followed by genotype clustering
using Klustercaller software (Kbiosciences, Hoddesdon, UK).
The final number of analysed individuals differed by trait
because of different genotype success rates (we required indi-
viduals to have >85% of SNPs successfully genotyped for any
one trait typed) and, for fasting glucose, because we excluded
individuals with diabetes.
Fasting glucose SNPs We excluded participants with diabe-
tes as defined by use of glucose-lowering medication or
fasting glucose ≥7 mmol/l, since these individuals would
be on glucose-lowering agents, making their fasting glucose
levels uninformative. Appropriate samples were available
from 1,544 individuals, of which 18 (1%) failed four or
Table 1 Baseline characteristics of the enrolled participants
Characteristics Total Type 2 diabetic participant Non-diabetic participant p valuea
n 2,880 617 2,263
Age (years) 51.5±10.7 53.2±10.4 51.1±10.8 9.03×10−6
Muhajir, n (%) 2,073 (72.0) 482 (78.1) 1,591 (70.3)
Sindhi, n (%) 236 (8.2) 34 (5.5) 202 (8.9) 3.23×10−4
Punjabi, n (%) 90 (3.1) 22 (3.6) 68 (3.0)
Others, n (%) 481 (16.7) 79 (12.8) 402 (17.8)
BMI (kg/m2) 25.75±5.47 27.07±5.43 25.39±5.42 1.12×10−11
Waist circumference (cm) 89.67±12.44 94.11±11.65 88.45±12.38 9.03×10−25
Fasting glucose (mmol/l) 6.41±2.82 10.42±3.96 5.34±0.57 1.46×10−132
Systolic BP (mmHg) 136.86±23.65 143.66±24.63 135.00±23.03 1.20×10−14
Diastolic BP (mmHg) 86.02±12.79 88.97±12.43 85.48±12.84 1.82×10−5
Triacylglycerol (mmol/l) 1.78±1.07 2.24±1.39 1.66±0.93 1.83×10−21
Serum cholesterol (mmol/l) 4.86±1.02 5.02±1.13 4.82±0.98 3.98×10−5
Men, n (%) 1,376 (47.8) 264 (42.8) 1,112 (49.1) 0.005
Hypertensionb, n (%) 1,270 (44.1) 362 (58.7) 908 (40.1) 1.94×10−16
Data are mean±SD for all continuous quantitative traits
a For comparison of the characteristics between diabetic and non-diabetic individuals
b Defined as patient taking antihypertensive drugs, or as mean systolic BP ≥140 mmHg or mean diastolic BP ≥90 mmHg
Invited 
n=3,546
Consented
n=3,143 (88.6%)
Blood samples 
available
Phase I
n=2,880 (91.6%)
Fasting glucose  
SNPs genotyped 
SNPs (n=16)
n=2,006 (69.7%)
aSamples with 
minimum 
proportion of SNPs 
called (13/16)
n=1,526 (98.8%)
Triacylglycerol 
SNPs genotyped
SNPs (n=10)
n=2,111 (73.3%)
Samples with 
minimum 
proportion of SNPs 
called (9/10)
n=2,051 (97.2%)
BMI SNPs 
genotyped
SNPs (n=5)
n=2,004 (69.6%)
Samples with 
minimum 
proportion of SNPs 
called (4/5)
n=1,755 (87.6%)
BP SNPs 
genotyped
SNPs (n=25)
n=1,833 (63.6%)
Samples with 
minimum 
proportion of SNPs 
called (23/25)
n=1,818 (99.2%)
Fig. 1 Flow diagram of study procedures. aParticipants with type 2
diabetes excluded n0462 (23%), where per cent is of n02,006
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more of the 16 attempted SNPs in the batch; these samples
were excluded. The call rates were therefore generated from
a subset of 1,526 samples, for which at least 13 of 16 SNPs
were called (Fig. 1). Call rates by SNP in these 1,526
samples ranged from 96.81% to 99.4%.
Triacylglycerol SNPs We used 2,111 participants, including
those with diabetes. Of these, 60 (3%) failed two or more of
the ten attempted SNPs in the batch and we excluded these
samples. The call rates were therefore generated from a
subset of 2,051 samples, for which at least nine of ten SNPs
were called (Fig. 1). Call rates by SNP ranged from 98.5%
to 100%.
BMI SNPs We used 2,004 participants, including those with
diabetes. Of these, 249 (12%) failed two or more of the five
attempted SNPs in the batch and were excluded. The call
rates were therefore generated from a subset of 1,755 sam-
ples, for which at least four of the five SNPs were called
(Fig. 1). Call rates by SNP ranged from 88.7% to 99.4%.
Blood pressure SNPs We used 1,833 samples. Of these, 15
(0.8%) failed 22 or more of the 25 attempted SNPs in the
batch and were excluded. The call rates were therefore
generated from a subset of 1,818 samples, for which at least
23 of 25 SNPs were called (Fig. 1). Call rates by SNP
ranged from 94.2% to 98.6%.
Statistical analyses
Association of SNPs with phenotypes in South Asians We
log10-transformed triacylglycerol levels, and systolic and
diastolic blood pressure. Fasting glucose did not require
transformation. We generated within-study z scores for fast-
ing glucose and log10-transformed triacylglycerol using the
mean and SD of the samples. We used individual SNPs as
independent variables and outcome measures as dependent
variables in a per-allele test, with age, sex, BMI, ethnicity
and clustering of household member. We coded ethnicity as
a non-ordinal value of 1, 2, 3 and 4 for the Muhajir, Sindhi,
Punjabi and other ethnicities respectively. For individual
SNP associations, we did not have adequate power to rep-
licate the effects observed in European samples, and we did
not correct single SNP analyses for multiple testing. Instead,
we report the number of SNPs associated in the same
direction as European associations at p<0.05 and compare
this with the one of 20 SNPs expected by chance. We also
tested the significance of genetic risk scores that combine
information from all known variants. For these tests we had
sufficient power, and based on the combined variants
explaining >0.7% of the phenotypic variance and a minimal
sample size of 1,500 individuals, we had >89% power to
detect effects at p00.05.
We created weighted allele scores and accounted for the
varying, previously reported effect sizes of each SNP using
Eq. (1), where w is the β-coefficient from the individual
regressions of SNP genotype against the outcome.
Weighted score ¼ w1  SNP1ð Þ þ w2  SNP2ð Þ
þ :::::::::::::: þ wn  SNPnð Þ ð1Þ
We rescaled the weighted score to reflect the number of
available SNPs using Eq. (2) as described in Lin et al. [18]:
Allele score ¼ Weighted score Number of SNPs available
Sum weight of the available SNPs
ð2Þ
We used this allele score as the independent variable, and
fasting glucose, triacylglycerol, BMI and systolic or diastolic
blood pressure as the dependent variables, with age, sex, eth-
nicity, clustering of householdmember and BMI (except for the
BMI analysis) as covariates in linear regression analyses.
For all traits, we also performed sensitivity analysis by
computing the allele score based on only those alleles asso-
ciated with the dependent variables at p<0.05, and assessed
their significance and the variability that was explained for
each model.
We also evaluated the association between SNPs and sec-
ondary phenotypes. For this, we used the weighted allele score
as independent variable and type 2 diabetes status (defined as
use of glucose-lowering medications or a fasting blood glu-
cose level of ≥7.0 mmol/l), hypertension status (defined as
mean systolic blood pressure ≥140 mmHg or mean diastolic
blood pressure ≥90 mmHg or taking anti-hypertensive med-
ication) or hypertriacylglycerolaemia (defined as serum
triacylglycerol >1.7 mmol/l) as the dependent variables in
logistic regression analyses, with age and sex as covariates.
Mendelian randomisation and instrumental variables
analysis We performed a series of instrumental variables
(IV)-basedMendelian randomisation analyses on several pairs
of traits as described below. We used the weighted allele score
associated with the primary trait as the ‘instrument’ to test the
relationship between each pair of primary and secondary
phenotypes. An IVanalysis relates the variation in the poten-
tially causal risk factor of interest (here one of the quantitative
traits) that is influenced by the ‘instrument’ (here the weighted
allele score) to the outcome (here one of the quantitative traits
or type 2 diabetes). This method assumes that the IV (1) is not
associated with measured or unmeasured confounders (likely
to be true for genetic variants) [11] and (2) is only related to
the outcome via its effect on the risk factor. This produces an
estimate of the causal effect in a similar way to an intention to
treat analysis in a randomised controlled trial [11]. To ensure
our tests were as close as possible to meeting these
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assumptions, we excluded two SNPs (in or near GCKR and
FADS1) known to have multiple effects on metabolic
phenotypes.
When the outcome was a continuously distributed trait,
we performed the IV estimation for each outcome in each
study using the two-stage least squares estimator, imple-
mented in the Stata command ‘ivreg2’. We tested for a
difference between the IV and observational estimates using
the Durbin–Wu–Hausman test of endogeneity.
When the outcome was a dichotomous trait (type 2 diabetes
case–control status) we performed IV analysis using a logistic
control function estimator. The analysis was performed in two
stages. In the first stage, we assessed the observational associ-
ation between the weighted allele score and the triacylglycerol
z score. We saved the predicted values and residuals from this
regression model. In the second stage, we used the predicted
values from stage 1 as the independent variable (reflecting an
unconfounded estimate of triacylglycerol levels due to these
genotypes) and diabetes status as the dependent variable in a
logistic regression analysis. The residuals from stage 1 were
included as a covariate, representing residual variation in tri-
acylglycerol levels that is not due to these genotypes. We then
used a Wald test to assess the evidence of any difference
between the predicted values coefficient (IV estimate of the
causal effect of triacylglycerol levels on type 2 diabetes) and
the residuals coefficient as a test of endogeneity.
The sensitivity analysis for the IVanalysis was performed
using the weighted allele score from the model only with
alleles significantly associated with the outcomes.
Given a minimum sample size of 1,500, we had 80%
power, at p<0.05, to detect combinations of genetic variants
that explain >0.5% of phenotypic variance. It is difficult to
estimate the statistical power of Mendelian randomisation
tests, but an approximate method is to take the product of
the SNP–primary trait and primary trait–secondary trait
effects. For example, an effect of 0.5% variance would require
a SNP–primary trait association explaining 5% variance and a
primary trait–secondary trait association explaining 10% var-
iance. Most associations in our study were weaker than this
and power therefore lower than 80% in most tests. However,
given that these calculations are very approximate, we present
the results of the tests, which in themselves provide better
power calculations for further study [19, 20]. All statistical
analyses were performed in Stata/IC v.12.1 for Windows
(Stata, College Station, TX, USA).
Results
Study procedures
Figure 1 illustrates the study flow diagram. Of the 3,546
invited participants aged 40 years or above, 3,143 (88.6%)
consented to enrol in the population-based study. We
attempted genotyping of 2,131 individuals from whom
DNA was available at the time of the genetic study.
Fasting glucose SNPs
Results from the individual 16 SNPs and the weighted allele
score are shown in Table 2. Of the 16 SNPs, seven were
associated with fasting glucose at p<0.05 (all with the same
allele direction as reported in Europeans, p00.00001, bino-
mial, compared with the number expected by chance), and
the weighted allele score was very strongly associated with
fasting glucose (p08.9×10−9). Together the SNPs explained
2.9% (95% CI 1.2, 4.6%) of the variance in fasting glucose
or 3.4% in sensitivity analysis consisting of only the seven
SNPs at p<0.05 as shown in electronic supplementary mate-
rial (ESM) Table 1, a finding that is similar to the 3% (95% CI
2.7, 3.3%) reported in Europeans [7]. The association of the
weighted allele score with fasting glucose is shown in Fig. 2a.
Triacylglycerol SNPs
Results from the individual ten SNPs and the weighted
allele score are shown in Table 3. Of the ten SNPs, six were
associated with triacylglycerol at p<0.05 (all with the same
allele direction as reported in Europeans, p00.000005, bi-
nomial, compared with the number expected by chance),
and the weighted allele score was very strongly associated
with triacylglycerol (p01.3×10−25). Together the SNPs
explained 5.5% (95% CI 3.5, 7.5%) of the variance in
triacylglycerol or 5.4% in sensitivity analysis consisting of
only the six SNPs at p<0.05 (ESM Table 1), which is
slightly less, based on 95% CIs, than the 7.4% (95% CI
6.7, 8.1%) reported in Europeans [9]. The association of the
weighted allele score with triacylglycerol levels is shown in
Fig. 2b.
BMI SNPs
Results from the individual five SNPs and the weighted
allele score are shown in Table 4. Of the five SNPs, two
were associated with fasting glucose (p00.007 and p0
0.059) FTO and GNPDA2, respectively, with the same allele
direction as reported in Europeans (p00.045, binomial,
compared with the number expected by chance); the weight-
ed allele score was associated with BMI (p00.00028). To-
gether the SNPs explained 0.7% (95% CI −0.2, 1.6%) (or
0.9% in sensitivity analysis consisting of the two most
strongly associated SNPs [ESM Table 1]) of the variance
in BMI, consistent with the 1.4% (95% CI 1.3, 1.5%)
reported in Europeans for a wider set of 32 SNPs [10].
The association of the weighted allele score with BMI is
shown in Fig. 2c.
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Blood pressure SNPs
Results from the individual 25 SNPs and the weighted allele
score are shown in Table 5. Of the 25 SNPs, four were
associated with systolic and diastolic blood pressure at p<
0.05 (all with the same allele direction as reported in Euro-
peans, p00.068, binomial), and the weighted allele score
was very strongly associated with systolic blood pressure.
Together the SNPs explained 1.2% (95% CI 0.02, 2.38%)
and 1.8% (95% CI 0.4, 3.2%) of the variance in systolic
and diastolic blood pressure, respectively (0.9% and 1.3%,
respectively, in sensitivity analysis [ESM Table 1]). These
estimates of variance in systolic and diastolic blood
pressure are similar to the 0.92% (95% CI 0.80, 1.04)
and 0.94% (95% CI 0.82, 1.06) reported in Europeans
[12]. The associations of the weighted allele score with
systolic and diastolic blood pressure are shown in
Fig. 2d, e.
Association of SNPs with secondary phenotypes
We observed a significant association between the weighted
allele score of BMI and hypertriacylglycerolaemia (p0
0.014). No other significant associations were detected
(Table 6).
Mendelian randomisation analysis
Significant observational associations were present between
primary and secondary phenotypes as seen in Table 7, ex-
cept between BMI and systolic blood pressure. For every 1
SD increase in log10-transformed triacylglycerol levels, the
OR (95% CI) for type 2 diabetes was 1.77 (95% CI 1.59,
1.98), p01.38×10−24. Each 1 SD increase in log10-trans-
formed triacylglycerol levels was associated with a 0.039
SD (95% CI 0.029, 0.049) increase in fasting glucose levels.
Every one unit increase in BMI was associated with a 0.353
Table 2 Effects of 16 fasting glucose SNPs on fasting glucose in South Asian and European individuals
Gene Reference study South Asian
SNP Nearest genea Allele
(effect/other)
EAF Effect
size
95% CI EAF Effect
sizeb
95% CI p value
rs10830963 MTNR1B G/C 0.30 0.067 (0.061, 0.073) 0.38 0.180c (0.111, 0.248) 2.85×10−7
rs560887 G6PC2 C/T 0.70 0.075 (0.069, 0.081) 0.89 0.204c (0.098, 0.309) 0.0002
rs174547 FADS1 T/C 0.64 0.017 (0.011, 0.023) 0.85 0.112c (0.019, 0.205) 0.019
rs7903146 TCF7L2 T/C 0.28 0.023 (0.015, 0.031) 0.30 0.093c (0.019, 0.167) 0.013
rs2191349 DGKB–
TMEM195e
T/G 0.52 0.030 (0.024, 0.036) 0.61 0.082c (0.014, 0.150) 0.019
rs7034200 GLIS3 A/C 0.49 0.018 (0.012, 0.024) 0.53 0.078c (0.010, 0.145) 0.024
rs340874 PROX1 C/T 0.52 0.013 (0.007, 0.019) 0.53 0.073c (0.005, 0.141) 0.034
rs179884 GCK (proxy
rs4607517)
T/G 0.16 0.062 (0.054, 0.070) 0.26 0.061c (−0.015, 0.136) 0.116
rs7944584 MADD A/T 0.75 0.021 (0.015, 0.027) 0.82 0.086c (0.000, 0.172) 0.051
rs780094 GCKR C/T 0.62 0.029 (0.023, 0.035) 0.76 −0.038c (−0.116, 0.040) 0.334
rs11920090 SLC2A2 T/A 0.13 0.020 (0.012, 0.028) 0.16 −0.037c (−0.130, 0.055) 0.429
rs11605924 CRY2 A/C 0.49 0.015 (0.009, 0.021) 0.48 0.009c (−0.058, 0.076) 0.787
rs11708067 ADCY5 A/G 0.78 0.027 (0.021, 0.033) 0.76 −0.015c (−0.095, 0.064) 0.706
rs11071657 C2CD4B A/G 0.63 0.008 (0.002, 0.014) 0.72 0.010c (−0.067, 0.087) 0.796
rs10885122 ADRA2A G/T 0.87 0.022 (0.014, 0.030) 0.78 −0.024c (−0.104, 0.057) 0.564
rs11558471 SLC30A8 A/G 0.68 0.027 (0.019, 0.035) 0.74 0.047c (−0.031, 0.125) 0.239
Weighted allele score 0.057d (0.041, 0.074) 3.44×10−12
South Asians, n01,526
EAF, Effect allele frequency
a Nearest gene information as in Dupuis et al [7]
b Adjusted for age, sex, BMI, ethnicity and clustering of household member
c Effect size for change in fasting glucose z score per fasting glucose-raising allele per individual SNPs
d Effect size for change in fasting glucose z score per unit increase in weighted allele score
e TMEM195, also known as AGMO
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(95% CI 0.224, 0.482) mmHg increase of diastolic blood
pressure, and 0.045 SD (95% CI 0.035, 0.054) and 0.017
SD (95% CI 0.014, 0.020) increases in triacylglycerol and
fasting glucose, respectively (Table 7).
We found evidence against the hypothesis that genetical-
ly raised triacylglycerol levels are causally related to type 2
diabetes status, in keeping with recently reported results in
Europeans [6]. We also found nominal evidence against the
hypothesis that raised fasting glucose levels are causally
related to triacylglycerol levels. In the triacylglycerol versus
type 2 diabetes status and fasting glucose versus triacylgly-
cerol analyses, the instrumental variable estimates of the
associations were lower than the observed associations
(p00.0003 and p00.05 for difference, respectively)
(Table 7). The sensitivity analysis revealed that findings
were consistent (ESM Table 2).
Discussion
We have tested the role of multiple genetic variants in five
metabolic phenotypes that are especially relevant to diabetes
and related outcomes in a Pakistani population. Our results
show that genetic risk scores containing multiple SNPs are
associated with fasting glucose levels, triacylglycerol levels,
BMI, and systolic and diastolic blood pressure in Pakistanis.
These risk scores have similar effects on the total phenotypic
variance explained in Pakistanis as they do in Europeans.
Fig. 2 The combined impact of
the 16 SNPs associated with
fasting glucose on fasting
glucose levels in the control
group (a). (b) The combined
impact, in all individuals, of
SNPs associated with
triacylglycerol (ten SNPs),
(c) BMI (five SNPs), and
(d) systolic BP (SBP) and (e)
diastolic BP (DBP) (25 SNPs)
on circulating triacylglycerol,
BMI, and systolic and diastolic
BP, respectively. Participants
were grouped by the total
number of trait-increasing
alleles at all trait-associated
SNPs. Grey bars, number
of individuals in each trait-
increasing allele group; circles,
mean trait z score within each
trait-increasing allele group;
error bars, SEM of the observed
mean trait; dashed line, fitted
mean trait level
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The distribution of allele frequencies in the study population
was also comparable to that reported in participants of
European origin, indicating that the attributable risk from
these genes is likely to be similar across the two populations
[7–10]. These results are consistent with data reported by
recent large GWAS for lipids [21] and blood pressure [12],
Table 3 Effects of ten triacylglycerol SNPs in South Asian and European individuals on triacylglycerol
Gene Reference study South Asian
SNP Nearest genea Allele
(effect/other)
EAF Effect
size
95% CI EAF Effect
sizeb
95% CI p value
rs7819412 XKR6–
AMAC1L2e
A/G 0.52 0.04 (0.001, 0.079) 0.46 −0.025c (−0.084, 0.034) 0.399
rs7679 PLTP C/T 0.19 0.07 (0.031, 0.109) 0.20 0.024c (−0.049, 0.097) 0.523
rs7557067 APOB A/G 0.78 0.08 (0.041, 0.119) 0.50 0.018c (−0.04, 0.076) 0.536
rs714052 MLXIPL A/G 0.88 0.16 (0.101, 0.219) 0.91 0.150c (0.048, 0.252) 0.004
rs662799 APOA5 G/A 0.06 0.25 (0.191, 0.309) 0.18 0.306c (0.231, 0.381) 1.77×10−15
rs328 LPL C/G 0.91 0.19 (0.151, 0.229) 0.91 0.131c (0.031, 0.232) 0.011
rs3135506 APOA5 C/G 0.06 0.24 (0.181, 0.299) 0.03 0.257c (0.091, 0.424) 0.002
rs2954029 TRIB1 A/T 0.66 0.11 (0.071, 0.149) 0.64 0.075c (0.014, 0.137) 0.016
rs17216525 CSPG3f,
CILP2, PBX4
C/T 0.93 0.11 (0.051, 0.169) 0.88 0.149c (0.059, 0.239) 0.001
rs10889353 ANGPTL3 A/C 0.67 0.05 (0.011, 0.089) 0.58 0.114c (0.055, 0.174) 0.0002
Weighted allele score 0.130d (0.105, 0.155) 2.9×10−21
South Asians, n02,051
EAF, Effect allele frequency
a Nearest gene information reported as in Kathiresan et al [9], except for rs328, which is from Kathiresan et al [8], and rs3135506 and rs662799
from De Silva et al [6]
b Adjusted for age, sex, BMI, ethnicity and clustering of household member
c Effect size for change in log10-triacylglycerol z score per triacylglycerol-raising allele for individual SNPs
d Effect size for change in log10-triacylglycerol z score per unit increase in weighted allele score
eAMAC1L2, also known as SLC35G5
fCSPG3, also known as NCAN
Table 4 Effects of five BMI SNPs in South Asian and European individuals on BMI
Gene Reference study South Asian
SNP Nearest genea Allele
(effect/other)
EAF Effect
size
95% CI EAF Effect
sizeb
95% CI p value
rs9939609 FTO A/T 0.42 0.390 (0.361, 0.429) 0.30 0.10c (0.027, 0.171) 0.007
rs10767664 BDNF A/T 0.78 0.190 (0.131, 0.249) 0.71 −0.04c (−0.111, 0.026) 0.224
rs10938397 GNPDA2 G/A 0.40 0.180 (0.141, 0.219) 0.40 0.06c (−0.002, 0.123) 0.059
rs543874 SEC16B G/A 0.19 0.220 (0.083, 0.357) 0.15 0.03c (−0.052, 0.121) 0.431
rs7359397 SH2B1 T/C 0.43 0.150 (0.111, 0.189) 0.22 0.01c (−0.071, 0.082) 0.885
Weighted allele score 0.04d (0.014, 0.072) 0.004
South Asians, n01,755
EAF, Effect allele frequency
a Nearest gene information as previously reported [10]
b Adjusted for age, sex, ethnicity and clustering of household member
c Effect size for change in BMI z score per BMI-raising allele for individual SNPs
d Effect size for change in BMI z score per unit increase in weighted allele score
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and provide further evidence that the majority of variants
identified in GWAS have similar effects in South Asian pop-
ulations to those in Europeans. This consistency between
genetic effects in Pakistanis and Europeans probably reflects
generally similar patterns of linkage disequilibrium and con-
sistent biological factors between Europeans and Asians, de-
spite the frequently very different environmental components.
Table 6 Observed association of weighted allele scores for triacylglycerol, fasting glucose and BMI SNPs with secondary phenotypes
Weighted allele scores Secondary phenotype n OR (95% CI) p value
Triacylglycerol Type 2 diabetesa 2,051 0.97 (0.91, 1.04) 0.410
Fasting glucose Hypertriacylglycerolaemiab 1,526 0.99 (0.96, 1.03) 0.648
BMI Hypertensionc 1,329 0.98 (0.91, 1.06) 0.696
BMI Hypertriacylglycerolaemiab 1,351 1.10 (1.02, 1.18) 0.014
a Type 2 diabetes status defined as use of glucose-lowering medications or fasting blood glucose level of ≥7.0 mmol/l
b Hypertriacylglycerolaemia defined as serum triacylglycerol >1.70 mmol/l
c Hypertension defined as taking antihypertensive drugs, or mean systolic BP ≥140 mmHg or mean diastolic BP ≥90 mmHg
Table 7 Mendelian randomisation analyses
Participants Phenotype Change in secondary phenotype IV estimate of change in
secondary phenotype
Observed vs
IV estimates
n Primary Secondary Effect (95% CI) p value Effect (95% CI) p value p value for
difference
2051 Triacylglycerol Type 2 diabetesb 1.769a (1.586, 1.974) 1.38×10−24 0.795a (0.498, 1.269) 0.336 0.0003
1526 Fasting glucose Triacylglycerolc 0.186 (0.137, 0.236) 1.02×10−13 −0.123 (−0.458, 0.212) 0.47 0.05
1584 Triacylglycerol Fasting glucosed 0.039 (0.029, 0.049) 4.44×10−15 0.007 (−0.036, 0.050) 0.75 0.13
1349 BMI SBPe −0.043 (−0.277, 0.190) 0.72
1349 BMI DBPf 0.353 (0.224, 0.482) 8.11×10−8 0.314 (−0.979, 1.607) 0.63 0.95
1349 BMI Triacylglycerolg 0.045 (0.035, 0.054) 1.54×10−14 0.095 (−0.004, 0.194) 0.06 0.30
1349 BMI Fasting glucoseh 0.017 (0.014, 0.020) 2.14×10−25 0.011 (−0.020, 0.042) 0.50 0.70
Correlations between primary traits and secondary traits based on standard observed data and correlations calculated using an instrumental variable
analysis, where the ‘instrument’ is the weighted allele score for the primary trait. If no association between traits was observed in standard analyses,
we did not proceed with IV analysis
DBP, Diastolic blood pressure; SBP, Systolic blood pressure
a OR; type 2 diabetes patients in analysis, n0467
b For every 1 SD increase in log10-triacylglycerol levels (millimoles per litre), the odds of type 2 diabetes was 1.77 (95% CI 1.59, 1.98); however,
the weighted allele score of log10-triacylglycerol levels was not associated with type 2 diabetes in IV analysis (p00.336)
c Each 1 SD increase in fasting plasma glucose (millimoles per litre) was associated with a 0.186 (0.137, 0.236) SD increase in log10-triacylglycerol
(millimoles per litre) levels in linear regression analysis; however, the weighted allele score of fasting glucose was not associated with log10-
triacylglycerol level in IV analysis (p00.47)
d Each 1 SD increase in log10-triacylglycerol (millimoles per litre) was associated with a 0.039 (0.029, 0.049) SD increase in fasting glucose levels
(millimoles per litre) in linear regression analysis; however, the weighted allele score of log10-triacylglycerol was not associated with fasting
glucose levels in IV analysis (p00.75)
e Each 1 unit increase in BMI (kilograms per square metre) was associated with a −0.043 (−0.277, 0.190) decrease in SBP (millimetre of mercury)
in linear regression analysis
f Each 1 unit increase in BMI (kilograms per square metre) was associated with a 0.353 (0.224, 0.482) increase in DBP (millimetre of mercury) in
linear regression analysis; however, the weighted allele score of BMI was not associated with DBP in IV analysis (p00.63)
g Each 1 unit increase in BMI (kilograms per square metre) was associated with a 0.045 (0.035, 0.054) SD increase in log10-triacylglycerol
(millimoles per litre) in linear regression analysis; however, the weighted allele score of BMI was not associated with log10-triacylglycerol in IV
analysis (p00.06)
h Each 1 unit increase in BMI (kilograms per square metre) was associated with a 0.017 (0.014, 0.020) SD increase in fasting glucose (millimoles per
litre) in linear regression analysis; however, the weighted allele score of BMI was not associated with fasting glucose levels in IVanalysis (p00.50)
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A second aim of our study was to use genetic risk scores
to help understand possible major causal directions between
metabolic traits. Further studies are needed to increase sta-
tistical power for these tests. However, we did observe
evidence that genetically influenced, raised triacylglycerol
and glucose levels do not causally affect type 2 diabetes risk
and triacylglycerol levels, respectively. The lack of evidence
that genetically influenced triacylglycerol levels causally
affect type 2 diabetes risk is consistent with recent evidence
from Europeans [6].
The strengths of our study include its population-
based design, which means the effect size estimates
and proportions of variance explained are likely to be
representative of the situation in Pakistani individuals.
We have also brought together information from several
traits in one study, allowing a simple comparison of
effects between traits, and between Europeans and
South Asians.
There are some limitations to this study. First, we did not
use all confirmed SNPs for all traits; for example, recent
publications have identified additional variants associated
with triacylglycerol levels and BMI [10, 21]. However, the
SNPs we used represent most of those with the strongest
effects on these traits and account for the majority of the
phenotypic variance reported for known SNPs in Europeans
[10, 21]. Second, our sample was representative of Karachi
and thus predominantly consists of a single ethnic subgroup,
i.e. Muhajirs (representative of North Indian descent); it
remains to be evaluated whether our findings can be gener-
alised to South Indian populations. Finally, the study was
possibly underpowered to perform robust Mendelian ran-
domisation analyses, although the estimates of our IV results
(Table 7) do provide more meaningful power estimates for
larger studies [2, 17].
It should also be emphasised that we did not study the
impact of genetic risk score on BMI, fasting glucose, tria-
cylglycerol and blood pressure levels in relation to other
environmental risk factors (e.g. diet, physical activity) in
this population. These metabolic risk factors could have
population-specific familial clustering and could potentially
interact with the genetic scores. This may be particularly
relevant in native South Asian populations exposed to
in-utero nutritional deficiencies with the subsequent
enhanced susceptibility to metabolic disorders with
weight gain [22].
In conclusion, our analyses provide valuable evidence
that the relationships between genetic variants associated
with important type 2 diabetes-related traits are similar
in Pakistanis and Europeans. Our instrumental variable
analysis findings, moreover, suggest that genetic risk
scores may help disentangle the causal relationships
between type 2 diabetes-related traits in larger sample
sizes.
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